Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121

Company announcement
Avexa files to extend ATC patent life

Melbourne, Australia – 23rd November 2011 – Melbourne-based biotechnology company Avexa Limited [ASX:AVX] today announced that it has filed two new patents covering the company’s Apricitabine (ATC) program. The two patents are based around the clinical findings identified by the company following the full analysis of the Phase II/III data set.

Dr Jonathan Coates, Avexa’s Interim Chief Executive Officer and Chief Scientific Officer, said: “These patents have real commercial application as they are focused on the use of ATC and its synergistic benefits when taken with either of two existing marketed drugs. These new patents dramatically improve the IP position for the company’s ATC program”.

The success in the treatment of HIV-1 infection by drug combinations has been known for some time. The results of our recent studies show that, unexpectedly, a number of marketed drugs work better with ATC than would have been predicted from historical knowledge, and considerably better than in combination with lamivudine, (ViiV’s anti-HIV agent also known as 3TC).

The new filings will add to the existing patent portfolio for ATC and could potentially provide patent protection for the ATC program. The filings have only recently been submitted; the company will continue to update shareholders on the progress of these filings, as well as other activities around the ATC program.

“The use of these new findings is one example of how Avexa is working to add shareholder value and increase the potential of the ATC program, while keeping expenditure under control,” said Avexa’s Chairman Mr Iain Kirkwood.

For more information:

Mr Iain Kirkwood
Chairman Avexa
Ph: +61 3 9208 4300

Dr Jonathan Coates
Interim CEO & CSO
Ph: +61 3 9208 4300

Richard Allen
Oxygen Financial Public Relations
Ph: + 61 3 9915 6341

About Avexa Limited

Avexa Limited (www.avexa.com.au) is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa’s key projects include apricitabine (ATC) for the treatment of drug-resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections.

www.avexa.com.au